Comments on ICER’s Draft Evidence Report on Plinabulin and Trilaciclib Chemotherapy-Induced Neutropenia
February 22, 2022
ICER has announced its intent to issue a final evidence report in this review without first holding a public hearing, a highly unusual decision. Removing the most direct opportunity for patients to contribute to this review flies in the face of ICER’s pledge to incorporate more patient input.
Tags: ICER, OncologyCategorized in: Analysis